STAGE IV RENAL CELL CANCER AJCC V8
Clinical trials for STAGE IV RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug trial aims to halt growth of advanced tumors with genetic flaw
Disease control OngoingThis study is testing a drug called adavosertib in people with advanced solid tumors that have spread and have a specific genetic change called SETD2-deficiency. The goal is to see if the drug can shrink or stop the growth of these tumors by blocking enzymes the cancer cells need…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Radiation zaps scattered tumors, aims to delay harsh drugs
Disease control TerminatedThis study is testing if precisely targeted radiation can control kidney cancer that has spread to only a few other body sites. The goal is to see if this approach can delay or avoid the need for stronger, body-wide drug treatments. It involves 123 adults with a limited number of…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Gut bacteria boost: could a probiotic supercharge cancer treatment?
Disease control OngoingThis early-stage study is testing if adding a probiotic called CBM588 to standard cancer drugs (cabozantinib and nivolumab) can help patients with advanced kidney cancer. The probiotic aims to improve the mix of 'good' bacteria in the gut, which might help the body's immune syste…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Personalized immune cells tested to fight five tough cancers
Disease control TerminatedThis early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo tested for aggressive, rare kidney cancer
Disease control OngoingThis study is testing whether adding a new drug called ixazomib to two standard chemotherapy drugs works better for controlling an aggressive type of kidney cancer that has spread. It is for patients aged 12 and older whose cancer has progressed after other treatments and who hav…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test Triple-Threat drug combo against Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a combination of cancer drugs for people with advanced cancers of the urinary system (like bladder and kidney cancer) that have spread. The trial combines a pill (cabozantinib) that aims to block tumor growth with one…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Head-to-Head kidney cancer drug trial seeks better control
Disease control OngoingThis study compares two existing drugs, cabozantinib and sunitinib, to see which is safer and more effective at controlling advanced kidney cancer that has spread. It is for patients with specific, less common types of kidney cancer. Participants are randomly assigned to take one…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Berry boost for cancer fight? trial tests natural Add-On to immunotherapy
Disease control TerminatedThis early-stage study is testing if adding a natural berry supplement called camu camu makes standard immunotherapy drugs work better for people with advanced kidney cancer that has spread. The main goal is to check if the combination is safe and to find the right dose of camu c…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New Two-Drug attack on tough, spreading cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for tough kidney cancer: can a combo therapy outperform standard care?
Disease control OngoingThis study is for people with advanced papillary kidney cancer that has spread. It compares the standard drug cabozantinib alone against cabozantinib combined with a newer immunotherapy drug called atezolizumab. The goal is to see if the two-drug combination can better control th…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Scientists test new Cancer-Fighting duo in early trial
Disease control OngoingThis early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Could tighter blood pressure control make cancer treatment safer?
Disease control OngoingThis study is testing whether keeping blood pressure very low (under 120) is better than the usual target (under 140) for patients with advanced kidney or thyroid cancer who are starting specific cancer drugs. The goal is to see if this intensive approach is doable, safe, and hel…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug duo tested in fight against rare, aggressive kidney cancer
Disease control OngoingThis study is testing whether combining two cancer drugs works better than using just one to treat an aggressive form of kidney cancer that has spread or cannot be removed by surgery. The trial is enrolling patients of all ages, from children to adults. Researchers want to see if…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for tough kidney cancers: Head-to-Head drug battle begins
Disease control OngoingThis study compares two different drug treatments for people with advanced kidney cancer that has spread and continued to grow despite previous immunotherapy. Researchers want to see whether a combination of two drugs (lenvatinib plus everolimus) works better than a single drug (…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Radiation blitz before drugs: new hope for containing spread kidney cancer?
Disease control OngoingThis large, late-stage trial is testing if adding a precise, high-dose radiation treatment to the standard drug therapy helps people with kidney cancer that has spread to a limited number of other body sites. It will compare survival, side effects, and quality of life between pat…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Targeted radiation joins fight against bone pain in advanced kidney cancer
Disease control OngoingThis study is for people with advanced kidney cancer that has spread to their bones. It tests if adding a radioactive drug (radium-223) to a standard cancer pill (cabozantinib) works better than the pill alone. The main goal is to see if the combination can delay bone-related pro…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC
-
Major trial aims to boost survival for advanced kidney cancer
Disease control OngoingThis large, late-stage trial is testing if adding a drug called cabozantinib to a standard immunotherapy regimen helps patients with advanced kidney cancer that has spread. The study will compare how long patients live and how long their cancer is controlled on the new combinatio…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
Can a phone app ease the fear and anxiety of advanced cancer?
Symptom relief OngoingThis study is testing whether a mindfulness app is a practical tool to help people with advanced kidney cancer that has spread. It aims to see if using the app for 20-30 minutes a day, at least 4 days a week for 4 weeks, can help reduce anxiety, fear of the cancer returning, and …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Mar 31, 2026 12:12 UTC